Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 30 of 111, showing 5 Applications out of 555 total, starting on record 146, ending on 150

# Protocol No Study Title Investigator(s) & Site(s)

146.

ECCT/23/07/05   Sabin
    A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults    
Principal Investigator(s)
1. Prof. Videlis Nduba Nduba Nzioka
Site(s) in Kenya
KEMRI / CRDR, KEMRI Clinical Research Annex, Siaya County Referral Hospital Ground. P.O BOX 144-40600 ,Siaya, Kenya
 
View

147.

ECCT/23/06/05   ARNASA
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Jesse Gitaka
Site(s) in Kenya
1. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
2. Clinical Research Health Network (CREA-N) (Machakos county)
3. KEMRI-CRDR Siaya Clinical Research Annex (Siaya county)
4. KEMRI-Mtwapa Clinical Annex (Kilifi county)
5. University of Nairobi Clinical Research Centre (Nairobi City county)
6. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
 
View

148.

ECCT/23/06/09   Hibiscus Kid\'s Study
    A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Walter Otieno
2. Videlis Nduba
Site(s) in Kenya
1. Kombewa Clinical research Centre (Kisumu county)
2. KEMRI, Siaya Clinical Research Annex (Kisumu county)
 
View

149.

ECCT/23/06/08   TSCV3000
    Age-descending, randomized, placebo-controlled Phase 2 trial in three sites in sub-Saharan Africa to assess the safety and immunogenicity of a parenteral Trivalent Salmonella (S. Enteritidis/S. Typhimurium/S. Typhi Vi) Conjugate Vaccine (TSCV) versus placebo   
Principal Investigator(s)
1. RICHARD ONYANDO OMORE
Site(s) in Kenya
1. SIAYA COUNTY REFERRAL HOSPITAL (Siaya county)
2. ST. ELIZABETH LWAK HOSPITAL (Siaya county)
 
View

150.

ECCT/23/06/02   IMAGINE-TBM
    A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM).   
Principal Investigator(s)
1. Deborah Chepng\'eno Langat
Site(s) in Kenya
KEMRI/WRP CRC
 
View